Emerging Themes in Targeted Therapy Research for CLL
John F. Seymour, MBBS, PhD, discusses some emerging themes from recent research for targeted therapies as treatment of patients with chronic lymphocytic leukemia.
John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Cancer Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses some emerging themes in research for targeted therapies as a treatment for patients with chronic lymphocytic leukemia (CLL).
Targeted agents are here to stay, says Seymour. These agents are more effective, safer, and are less genotoxic than treatment with chemoimmunotherapy.
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More
Telehealth Continues to Show Importance Post COVID-19 in Rare Diseases
December 29th 2024In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases receiving medical care and why the rules from the COVID-19 era should be brought back to continue helping these patients.
Read More
